Cat. No. 3786
Alternative Names: SC 58635, Celebrex
Chemical Name: 4-[5-(4-Methylphenyl)-3-(trifluorom
Biological ActivitySelective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). Anti-inflammatory with shorter plasma half-life in vivo than SC 58121 (Cat. No. 2895). Displays chemopreventive activity in in vivo tumor models.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Harris et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60 2101. PMID: 10786667.
DeWitt (1999) Cox-2-selective Inhibitors: the new super aspirins. Mol.Pharmacol. 55 625. PMID: 10101019.
Penning et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J.Med.Chem. 40 1347. PMID: 9135032.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Celecoxib from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Celecoxib, supplier, Selective, cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, SC58635, Pfizer, Tocris Bioscience, Cyclooxygenase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective myeloperoxidase (MPO) inhibitorINCB 024360-analog
Potent indoleamine 2,3-dioxygenase (IDO) inhibitorLM 10
Selective tryptophan 2,3-dioxygenase (TDO) inhibitorNoxA1ds
Potent and selective NADPH oxidase 1 (NOX1) inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.